-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On Jan.
5, Metagenomi, a gene drug company with a range of wholly-owned next-generation gene-editing systems, announced the closure of a $100 million Series B+ funding round by Novo
Holdings, Catalio Capital Management and SymBiosis, co-led, with new and existing investor participation, including Leaps by
Bayer and Moderna, as well as initial Series B investors PFM Health Sciences and Farallon Capital
Management and a leading global investment firm
.
The $100 million financing brought the total Series B proceeds to $275 million, with more than 30 investors participating
.
In terms of financing, Novo
Ventures partner Dr.
Ray Camahart will join Metagenomi's board of directors
as an observer.
In February 2022, Metagenomi completed an expanded and oversubscribed $175 million Series B financing
.
Investors include: RA
Capital、Leaps by Bayer、Humboldt Fund、PFM Health Sciences、Farallon Capital
Management、Deep Track Capital、Frazier Life Sciences、Pura Vida
Investments, Surveyor Capital, Novo Holdings, BMS and Moderna, among others
.
Novo
Dr.
Ray Camahart, Partner at Ventures, said: "At Novo
At Holdings, our goal is to improve people's health and the sustainability
of society and the planet.
Metagenomi continues its impressive track record
in rapidly developing novel gene-editing systems and advancing them through preclinical validation.
With Metagenomi's next-generation technology platform, preclinical advances, numerous effective partnerships, and strong investors, we believe the company is well positioned to rapidly develop therapies
to treat multiple genetic diseases.
" ”
Ray Camahart, Partner at Ventures, said:
With Moderna and Ionis
Pharmaceuticals ($3 billion!) Ionis and Metagenomi enter into a strategic partnership) following the successful collaboration, Metagenomi has access to a healthy cash runway, and this additional funding will enable Metagenomi to advance its leading treatment program
through preclinical development and clinical proof-of-concept.
In addition, the company plans to specify more therapeutic targets for its proprietary gene drug pipeline, driven by its automated discovery engine and versatile gene-editing toolbox, to expand into more preclinical proof-of-concept studies
.
Brian, CEO and founder of Metagenomi
C.
Thomas said, "The end of the Series B deferred financing is a testament to the significant progress
we have made over the past year.
We further expanded our wholly-owned toolbox of next-generation gene editing technologies, began our first proof-of-concept study of in vivo gene editing in non-human primate (NHP), and strengthened our strategic business development alliance
.
This additional funding allows us to see initial clinical milestones and expand the pipeline
of in vivo gene editing applications.
" ”
Thomas said:
Original link: _mstmutation="1" _msthash="220731" _msttexthash="6493708">
